Does Rallies show 13F holders for LEGN?

Yes. Rallies tracks hedge fund and 13F ownership data for LEGN, including fund names, share counts, latest tracked quarter, and position changes when available.

Is LEGN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LEGN. It does not provide personalized investment advice.

LEGN (Legend Biotech) Stock Analysis - Hedge Fund Holdings

Legend Biotech (LEGN) is a publicly traded Healthcare sector company. As of May 21, 2026, LEGN trades at $27.67 with a market cap of $5.01B and a P/E ratio of 0.00. LEGN moved +4.36% today. Year to date, LEGN is +38.45%; over the trailing twelve months it is -6.48%. Its 52-week range spans $16.24 to $51.77. Analyst consensus is strong buy with an average price target of $55.90. Rallies surfaces LEGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns LEGN stock?

Hedge funds tracked by Rallies that own LEGN include Bridgewater Associates, Centerbook Partners, Panagora Asset, and Duquesne Family. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Legend Biotech.

LEGN Key Metrics

Key financial metrics for LEGN
Metric	Value
Price	$27.67
Market Cap	$5.01B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$51.77
52-Week Low	$16.24
Volume	794
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Top Hedge Funds Holding LEGN

Bridgewater Associates holds 225.45K shares of LEGN, changed +39.40% as of Mar 31, 2025.
Centerbook Partners holds 204.60K shares of LEGN, changed -3.95% as of Mar 31, 2026.
Panagora Asset holds 139.89K shares of LEGN, changed +0.00% as of Dec 31, 2025.
Duquesne Family holds 114.50K shares of LEGN, changed +0.00% as of Mar 31, 2024.

Latest LEGN News

Legend Biotech gains after Q1 2026 results highlight $597M CARVYKTI sales growth — May 12, 2026
Legend Biotech Q1 CARVYKTI® Sales Jump 62% to $597M on Global Expansion — May 12, 2026
Legend Biotech Adds Six CAR-T and Immunology Pioneers to Scientific Advisory Board — May 4, 2026
Legend Biotech Plans 20,000-Dose Carviti Capacity Boost, Seeks 50% Growth — Mar 10, 2026
Legend Biotech Boasts $555M Q4 CARVYKTI Sales, Profitability and 10,000 Patients Treated — Mar 10, 2026

Recent LEGN Insider Trades

Huang Ying sold 9.94K (~$87.14K) on Mar 25, 2026.

LEGN Analyst Consensus

11 analysts cover LEGN: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $55.90.

Common questions about LEGN

Who owns LEGN stock?: Hedge funds tracked by Rallies that own LEGN include Bridgewater Associates, Centerbook Partners, Panagora Asset, and Duquesne Family. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Legend Biotech.
Does Rallies show 13F holders for LEGN?: Yes. Rallies tracks hedge fund and 13F ownership data for LEGN, including fund names, share counts, latest tracked quarter, and position changes when available.
Is LEGN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LEGN. It does not provide personalized investment advice.